InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in Editorial Highlighting Breakthrough Genetic Medicine Platform
July 8, 2025
Calidi Biotherapeutics (NYSE American: CLDI) announced its feature in a NetworkNewsWire editorial discussing the company’s precision genetic medicine platform, which targets both primary and metastatic cancer tumors using engineered viruses. With global cancer diagnoses expected to reach 35 million annually by 2050, Calidi’s approach represents a potential breakthrough in addressing critical unmet needs. The company’s […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter
June 27, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company developing systemic oncolytic targeted immunotherapies, released a shareholder letter from CEO Eric Poma, PhD, outlining a transformative year for the company. Since Poma’s appointment in April 2025 and the addition of Dr. Guy Travis Clifton as Chief Medical Officer, Calidi has streamlined operations and advanced its […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Taps Biotech Veteran to Lead Next Phase of Growth
June 10, 2025
Calidi Biotherapeutics (NYSE American: CLDI) recently announced the appointment of Eric Poma, PhD, as its new chief executive officer and member of the board of directors. The company was featured in an article that reads, “As Calidi Biotherapeutics continues to pioneer targeted antitumor virotherapies, the appointment of Dr. Poma as CEO represents a strategic move […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Unveils Promising Data on CLD-401 at ASCO 2025
June 5, 2025
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads. The company unveiled promising new data on its lead RedTail platform candidate, CLD-401, at the American Society of Clinical Oncology (“ASCO”) Annual Meeting. The announcement reads, “Calidi has previously demonstrated […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) RTNova Shows Promise in Targeted Tumor Therapy
May 22, 2025
Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors. The innovative platform not only targets cancer cells effectively but also minimizes harm to surrounding healthy tissues, potentially improving treatment outcomes and reducing side effects. As global cancer […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Names Experienced Life Science Leader as New CEO
May 19, 2025
Effective leadership is a cornerstone of organizational success, particularly in the dynamic and high-stakes realm of biotechnology. Recognizing the pivotal role of seasoned leadership, Calidi Biotherapeutics (NYSE American: CLDI) has announced the appointment of Eric Poma, PhD, as its new Chief Executive Officer and member of the board of directors (https://ibn.fm/qMEu4). This strategic transition underscores Calidi’s […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances Redtail Virotherapy Platform and Reduces Q1 Losses
May 15, 2025
Calidi Biotherapeutics (NYSE American: CLDI) reported a Q1 2025 net loss of $5.0 million, narrowing from $7.2 million in the prior year, with R&D and G&A expenses also declining. The company highlighted FDA clearance of its IND for CLD-201, an allogeneic stem cell-based immunotherapy for solid tumors, and presented promising Redtail platform data at AACR […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Eyes Game-Changing Approach to Cancer Treatment
May 9, 2025
Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its innovative RTNova platform, which has successfully delivered transient gene-therapy payloads to targeted tumors. In addition, Calidi’s virotherapy demonstrated efficacy in killing more than 60 different tumor cell lines, showcasing the platform’s potential to revolutionize cancer treatment by enabling both tumor destruction and robust […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Committed to Advancing Cancer Care with Innovative RTNova Platform Research
April 30, 2025
Cancer remains one of the deadliest diseases worldwide. Globally, the World Health Organization reports that the number of deaths will surpass 9.7 million in 2024, with a projected 20 million new cancer cases diagnosed; WHO also noted that it anticipates the cancer burden increasing an estimated 77% by 2050 (https://ibn.fm/VfZlY). These numbers underscore the urgency […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Innovative RTNova Platform Research, Exemplifies Pivotal Role of Research
April 29, 2025
Cancer remains one of the most formidable health challenges worldwide, necessitating relentless research to uncover effective treatments. Continuous scientific inquiry has led to groundbreaking therapies, offering hope to millions. A recent development in this arena is Calidi Biotherapeutics’ (NYSE American: CLDI) announcement of promising preclinical results for its systemic RTNova platform, highlighting the critical role […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances RTNova Platform with IL15 Superagonist Payload
April 28, 2025
Calidi Biotherapeutics (NYSE American: CLDI) announced the selection of IL15 superagonist (IL15-IL15Ra) as the first therapeutic payload for its systemic antitumor virotherapy platform, RTNova. Preclinical data presented at the AACR Annual Meeting show that Calidi’s engineered vaccinia virus can deliver IL15 superagonist directly into the tumor microenvironment, significantly boosting immune response and tumor elimination while […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Grants Inducement Stock Option to New CEO Eric Poma
April 25, 2025
Calidi Biotherapeutics (NYSE American: CLDI) a clinical-stage biotechnology company advancing targeted antitumor virotherapies, announced the approval of an inducement non-qualified stock option grant to new Chief Executive Officer Eric Poma, Ph.D. The grant includes the option to purchase 726,412 shares at an exercise price of $0.469, the closing price of Calidi’s common stock on April […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Appoints Eric Poma as CEO to Lead Next Phase of Clinical Growth
April 23, 2025
Calidi Biotherapeutics (NYSE American: CLDI) announced the appointment of Eric Poma, Ph.D., as Chief Executive Officer and member of its Board of Directors, effective Apr. 22. He succeeds Allan Camaisa, who will continue as a Board member. Dr. Poma, a veteran biotech leader, brings over 30 years of experience, including roles at Molecular Templates (NASDAQ: […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Host Investor Webinar Highlighting Cancer Immunotherapy Pipeline
April 22, 2025
Calidi Biotherapeutics (NYSE American: CLDI) will host a live investor webinar on April 24, 2025, at 4:15 p.m. ET, featuring its new Chief Medical Officer, Dr. Guy Travis Clifton. The event will spotlight Calidi’s stem cell-based delivery platforms for oncolytic virus therapies, including the FDA-cleared CLD-201, which is advancing toward trials for solid tumors. Additional […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Receives FDA Clearance to Begin Trials for CLD-201 in Solid Tumors
April 17, 2025
Calidi Biotherapeutics (NYSE American: CLDI) announced FDA clearance of its Investigational New Drug application for CLD-201, an allogeneic stem cell-based virotherapy targeting solid tumors including breast cancer, head and neck cancer, and soft tissue sarcoma. Backed by preclinical data showing immune system evasion and potent tumor-killing ability, CLD-201 is now cleared to enter clinical development. […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Appoints Oncology Expert Dr. Guy Travis Clifton as Chief Medical Officer
April 10, 2025
Calidi Biotherapeutics (NYSE American: CLDI) has named Dr. Guy Travis Clifton as Chief Medical Officer, Consultant and Advisor. The appointment comes as Calidi advances clinical development of CLD-201, a virotherapy for solid tumors, following a recently filed Investigational New Drug application. Dr. Clifton brings over 17 years of oncology and clinical trial expertise, including leadership […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances Cancer Platforms, Reports Narrowed Loss for Q4 2024
April 2, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted immunotherapies, reported a reduced net loss of $4.1 million for Q4 2024, down from $8.2 million the prior year. The company highlighted significant progress across its three oncology platforms, including the IND filing for CLD-201 targeting solid tumors and continued clinical development of CLD-101 […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $3.9 Million Offering to Advance Immunotherapy Programs
April 1, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted immunotherapies, closed its previously announced registered direct offering and concurrent private placement with a single institutional investor, raising approximately $3.9 million in gross proceeds. The offering included 3,325,000 shares of common stock and pre-funded warrants for 2,728,000 shares, along with Series G warrants for […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces $3.9 Million Registered Direct Offering and Private Placement
March 28, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company advancing targeted immunotherapies, has entered into a securities purchase agreement with a single institutional investor for a registered direct offering of 3,325,000 shares of common stock at $0.65 per share, or pre-funded warrants in lieu of stock. Concurrently, the company will issue series G warrants to […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Encouraging Progress in Brain Cancer Trial with City of Hope
March 26, 2025
Calidi Biotherapeutics (NYSE American: CLDI) announced promising early results from a phase 1 clinical trial evaluating its CLD-101 investigational agent, a neural stem cell-based oncolytic virotherapy, in collaboration with City of Hope. The trial, targeting recurrent high-grade glioma, is the first to assess multiple weekly intracerebral doses of CLD-101. Fourteen participants have been treated so […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI): Poised in the Future of Oncology with Cutting-Edge Treatments
March 21, 2025
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of research and development of innovative treatments in the field of immuno-oncology. With cancer being the second leading cause of death globally, the company focuses on harnessing antitumor virotherapies and patented technologies designed to protect and potentiate the virotherapy during administration to […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) Novel Therapies Show Promise Against Aggressive Cancers
March 14, 2025
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company that is pioneering proprietary technology designed to attack solid tumors, empowering the immune system to combat cancer. The company was featured in a recent article that discussed its platform, which utilizes antitumor virotherapies that selectively infect and kill cancer cells while stimulating the body’s immune […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform
March 12, 2025
Calidi Biotherapeutics (NYSE American: CLDI) recently announced positive preclinical results for its systemic RTNova platform, demonstrating effective delivery of transient gene therapy payloads to targeted tumors. The tumor-specific virotherapy has shown efficacy across more than 60 tumor cell lines, with a unique vaccinia virus strain enveloped in a human cell membrane providing protection in the […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Stands at the Forefront of Integrating New Oncology Therapies
March 5, 2025
Calidi Biotherapeutics (NYSE American: CLDI) is leveraging innovative platforms in a commitment to transform cancer treatment using advanced biotechnology. “The company is pioneering therapies that combine stem cells with antitumor viruses to create powerful cancer treatments. Antitumor viruses or virotherapies selectively infect and destroy cancer cells while sparing normal cells and, when paired with stem […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Pioneers Systemic Virotherapy with RTNova Platform
March 5, 2025
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of developing innovative immunotherapies for cancer treatment. Most recently, the company has captured the spotlight for the development of its proprietary systemic platform, RTNova (https://ibn.fm/Z4pM3). The platform represents a significant advancement in systemic virotherapy, particularly in the utilization of enveloped virotherapies to […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) and OS Therapies (NYSE American: OSTX) to Appear on RedChip’s Bloomberg TV Show
February 28, 2025
Calidi Biotherapeutics (NYSE American: CLDI) and OS Therapies Inc. (NYSE American: OSTX) will be featured on RedChip’s Small Stocks, Big Money™ show, airing on Bloomberg TV this Saturday, March 1, at 7 p.m. ET. Andrew Jackson, CFO of Calidi, will discuss the company’s stem cell-based oncolytic virotherapy platform designed to enhance cancer treatment. Calidi’s lead […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Drives Growth with Strengthened Financial Position and Cutting-Edge Research
February 25, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, is making significant strides in the field of cancer immunotherapy. Known for its innovative approach to antitumor virotherapies, Calidi is focused on harnessing the power of its patented technology that protects and potentiates the virotherapy during administration (extracellular enveloped viruses in its systemic platform and stem […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Sees Growth, Potential in Oncology Drug Development, a Critical Frontier in Cancer Treatment
February 24, 2025
Cancer continues to be one of the most significant health challenges of our time, with its global impact growing every year. The increasing number of cancer diagnoses and related deaths underscores the urgent need for more effective treatments, including advanced oncology drugs. Companies such as Calidi Biotherapeutics (NYSE American: CLDI) are at the forefront of […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Launches “CLD-101” Trial for High-Grade Glioma at Northwestern
February 24, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted antitumor virotherapies, said Northwestern University/Northwestern Memorial Hospital is recruiting for its Phase 1B/2 clinical trial of “CLD-101” in newly diagnosed high-grade glioma patients. The company completed shipment of the first batch of CLD-101—comprising allogeneic neural stem cells loaded with the oncolytic adenovirus CRAd-S-pk7—to support […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focuses Innovation on Hard-to-Treat Tumors
February 21, 2025
Cancer remains a significant global health challenge, with certain types exhibiting particularly high mortality rates. Glioblastoma multiforme (“GBM”), triple-negative breast cancer (“TNBC”), sarcoma and lung cancer are among the most aggressive and deadly forms, necessitating urgent advancements in research and treatment. Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering proprietary technology designed […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focused on Advancing Stem Cell-Based Research Amid Rising Cancer Concerns
February 20, 2025
As 2025 approaches, cancer continues to be one of the most significant global health challenges. Projections indicate a sharp increase in cancer diagnoses, with new cases in 2024 expected to surpass 2 million annually in the United States for the first time. Globally, cancer incidence is expected to climb, driven by factors such as aging […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Host Investor Webinar on Feb. 5
January 29, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company advancing targeted antitumor virotherapies, will host an investor webinar on Feb. 5, 2025, at 4:15 p.m. ET. The event, organized by RedChip Companies, will feature CFO Andrew Jackson and CSO Antonio F. Santidrian, PharmD, PhD, discussing Calidi’s cell-based delivery platforms designed to enhance oncolytic virus-based cancer […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Ends SEPA Agreement Following Successful Fundraising
January 28, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company specializing in targeted antitumor virotherapies, reported a cash balance of approximately $9.6 million as of Dec. 31, 2024, and announced the termination of its Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., effective Jan. 23, 2025. Calidi secured $9.5 million in gross proceeds in […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Present Breakthrough Virotherapy Platform at AACR 2025
January 14, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company specializing in targeted antitumor virotherapies, announced its abstract, “Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic Sites,” has been accepted for presentation at the American Association for Cancer Research (“AACR”) Annual Meeting, April 25-30, 2025, in Chicago. The presentation will highlight Calidi’s proprietary RTNova […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Prices $4.25 Million Public Offering
January 13, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted immunotherapies, has priced its public offering of 5,000,000 shares of common stock at $0.85 per share, with gross proceeds expected to total approximately $4.25 million before fees and expenses. The offering, exclusively placed by Ladenburg Thalmann & Co. Inc., is set to close […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces Public Offering of Common Stock and Warrants
January 10, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on advanced immunotherapies, announced plans to offer shares of its common stock and/or pre-funded warrants in a public offering. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent. The offering’s size and terms depend on market conditions and are yet to be […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) at the Forefront of Cancer Treatment Innovation
December 12, 2024
Calidi Biotherapeutics (NYSE American: CLDI) was featured in a recent article that showcased the company as a compelling example of progress of emerging therapies and advances that are reshaping the fight against cancer. Calidi’s “recent data on its RTNova(TM) systemic enveloped virotherapy technology demonstrates the potential of cutting-edge solutions to revolutionize cancer care,” the article […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Data Demonstrates Potential of Innovative Solutions to Revolutionize Cancer Care
December 6, 2024
Cancer continues to be a leading cause of morbidity and mortality worldwide, affecting millions of lives every year. While advances in prevention, early detection and treatment have made strides in reducing the global cancer burden, innovation remains critical to achieving further breakthroughs. Emerging therapies, advanced diagnostic tools and groundbreaking research are reshaping the fight against […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Showcases Platform ‘Designed to Unlock New Possibilities in Cancer Therapy’
December 3, 2024
Calidi Biotherapeutics (NYSE American: CLDI) is focused on discovering more effective treatments amid projections from the American Cancer Society that 2024 will be the first year ever to see two million people diagnosed with cancer. “Calidi Biotherapeutics’ RTNova (‘CLD-400’) is an innovative systemic antitumor enveloped virotherapy designed to unlock new possibilities in cancer therapy. The […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Shares Data Supporting Innovative Proprietary Systemic Antitumor Platform
November 22, 2024
The American Cancer Society (“ACA”) has projected that 2024 will be the first year ever to see two million people diagnosed with cancer, which remains the second leading cause of death in the United States, after heart disease (https://ibn.fm/ADo2Q). Companies such as Calidi Biotherapeutics (NYSE American: CLDI) are working hard to discover more effective treatments […]